JP2023538945A5 - - Google Patents
Info
- Publication number
- JP2023538945A5 JP2023538945A5 JP2023513532A JP2023513532A JP2023538945A5 JP 2023538945 A5 JP2023538945 A5 JP 2023538945A5 JP 2023513532 A JP2023513532 A JP 2023513532A JP 2023513532 A JP2023513532 A JP 2023513532A JP 2023538945 A5 JP2023538945 A5 JP 2023538945A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- polypeptide chain
- antigen
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/110841 | 2020-08-24 | ||
| CN2020110841 | 2020-08-24 | ||
| CNPCT/CN2020/141398 | 2020-12-30 | ||
| CN2020141398 | 2020-12-30 | ||
| PCT/CN2021/114088 WO2022042488A1 (en) | 2020-08-24 | 2021-08-23 | Anti-ror1 antibodies and related bispecific binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538945A JP2023538945A (ja) | 2023-09-12 |
| JP2023538945A5 true JP2023538945A5 (cg-RX-API-DMAC7.html) | 2024-08-28 |
| JP7781859B2 JP7781859B2 (ja) | 2025-12-08 |
Family
ID=77946069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513532A Active JP7781859B2 (ja) | 2020-08-24 | 2021-08-23 | 抗ror1抗体及び関連の二重特異性結合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240010753A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4200336A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7781859B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230053602A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114085288A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021334677A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002895A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190117A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300760A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002181A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI907489B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022042488A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| CA3032430A1 (en) * | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN114539411B (zh) * | 2022-04-29 | 2022-11-11 | 山东博安生物技术股份有限公司 | 一种ror1抗体或其抗原结合片段 |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ror1結合タンパク質を発現する細胞を培養する方法 |
| CN118974090A (zh) * | 2022-04-02 | 2024-11-15 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| CA3262028A1 (en) * | 2022-07-15 | 2025-06-13 | Abl Bio Inc. | Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses |
| CN116836286A (zh) * | 2022-09-07 | 2023-10-03 | 中国科学院合肥物质科学研究院 | 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024094151A1 (en) * | 2022-11-03 | 2024-05-10 | Hansoh Bio Llc | Multi-specific antibody and medical use thereof |
| AU2024331841A1 (en) * | 2023-08-31 | 2026-03-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof |
| WO2025061032A1 (zh) * | 2023-09-18 | 2025-03-27 | 南京蓬勃生物科技有限公司 | 靶向人源ror1和cd3的双特异性抗体 |
| TW202542204A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商上海岸邁生物科技有限公司 | 融合蛋白及其用途 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| CN122376773A (zh) * | 2025-01-14 | 2026-07-14 | 正大天晴药业集团股份有限公司 | 靶向受体酪氨酸激酶样孤儿受体1的抗体药物偶联物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242014B2 (en) * | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| EP3252076B1 (en) * | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JP2017536341A (ja) * | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体 |
| EP3204415B1 (en) * | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| HK1253507A1 (zh) * | 2015-05-18 | 2019-06-21 | Eureka Therapeutics, Inc. | 抗 ror1 抗体 |
| HK1251480A1 (zh) * | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| CA3001941A1 (en) * | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
| CA3011419A1 (en) * | 2016-01-22 | 2017-07-27 | Janssen Biotech, Inc. | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same |
| AR108034A1 (es) * | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| CA3032430A1 (en) * | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| KR102999339B1 (ko) * | 2018-04-18 | 2026-07-31 | 엑셀리시스, 인코포레이티드 | 항-ror 항체 구조체 |
| EA202192103A1 (ru) * | 2019-01-29 | 2021-12-15 | Джуно Терапьютикс, Инк. | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) |
| CN111286512A (zh) * | 2019-06-05 | 2020-06-16 | 南京艾德免疫治疗研究院有限公司 | 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途 |
| KR20220035369A (ko) * | 2019-06-07 | 2022-03-22 | 아디맵 엘엘씨 | 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법 |
| TWI774137B (zh) * | 2019-11-26 | 2022-08-11 | 大陸商上海岸邁生物科技有限公司 | 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白 |
-
2021
- 2021-08-23 IL IL300760A patent/IL300760A/en unknown
- 2021-08-23 CN CN202110968072.5A patent/CN114085288A/zh active Pending
- 2021-08-23 AU AU2021334677A patent/AU2021334677A1/en active Pending
- 2021-08-23 WO PCT/CN2021/114088 patent/WO2022042488A1/en not_active Ceased
- 2021-08-23 US US18/042,762 patent/US20240010753A1/en active Pending
- 2021-08-23 CA CA3190117A patent/CA3190117A1/en active Pending
- 2021-08-23 TW TW110131088A patent/TWI907489B/zh active
- 2021-08-23 KR KR1020237005603A patent/KR20230053602A/ko active Pending
- 2021-08-23 EP EP21860323.1A patent/EP4200336A4/en active Pending
- 2021-08-23 CN CN202110969266.7A patent/CN113480656B/zh active Active
- 2021-08-23 MX MX2023002181A patent/MX2023002181A/es unknown
- 2021-08-23 BR BR112023002895A patent/BR112023002895A2/pt unknown
- 2021-08-23 JP JP2023513532A patent/JP7781859B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020359928B2 (en) | CD3-targeting antibody, bispecific antibody and use thereof | |
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| JP2024510098A (ja) | 抗GPRC5DxBCMAxCD3三重特異性抗体およびその使用 | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2021512630A5 (cg-RX-API-DMAC7.html) | ||
| JP2022551836A (ja) | Bcmaを標的とする抗体、二重特異性抗体及びその用途 | |
| CN106831996B (zh) | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 | |
| JP2018502050A5 (cg-RX-API-DMAC7.html) | ||
| JP2021520832A5 (cg-RX-API-DMAC7.html) | ||
| JP7728595B2 (ja) | 二重特異性抗体及びその用途 | |
| CN111093702A (zh) | 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗 | |
| CN118946592A (zh) | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 | |
| JP2024543822A5 (cg-RX-API-DMAC7.html) | ||
| CN116135884A (zh) | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| WO2023036215A1 (zh) | 双特异性抗原结合分子及其应用 | |
| JP2026508244A (ja) | 抗Nectin-4抗体及びそれを含む多重特異性抗体 | |
| JP2025525885A (ja) | Gucy2cとcd3に特異的に結合する抗原結合分子及びその医薬的使用 | |
| WO2024094151A1 (en) | Multi-specific antibody and medical use thereof | |
| KR20260035361A (ko) | 폴리오바이러스 수용체에 대한 항체 및 이의 용도 | |
| CA3281557A1 (en) | Trispecific antigen-binding molecule and use thereof | |
| CA3281554A1 (en) | Trispecific antigen-binding molecule and use thereof | |
| HK40101629A (en) | Bispecific antibody containing anti-cldn18.2 antibody, and pharmaceutical composition and use thereof | |
| WO2024223710A1 (en) | Novel egfr binding proteins | |
| KR20250158060A (ko) | 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법 |